Lymenet.de - Home
Neues auf Lymenet.de
Ergänzungen und Veränderungen
Über
Lyme-Borreliose
Klinische
Informationen
Symptome, Diagnose, Behandlung
Hintergrund & medizinische Fachliteratur
Lyme und Multiple Sklerose
Lyme
und ALS
Berichte
über Tagungen und Info-Veranstaltungen
Krankenversicherungen
Menschenrechte,
Ethik
Beiträge
von Selbsthilfegruppen
Artikel
in Zeitschriften und TV
Lexikon
Kontakte
Links
Suchen
FAQs: Häufig gestellte Fragen
Hinweise zum Offline-Lesen
Dateistruktur von Lymenet.de
|
Medical Literature
Medizinische Fachliteratur
International Conference on Lyme Disease and Other Spirochetal and Tick-Borne Disorders (cached versions)
Abstracts von Veröffentlichungen
in medizinischen Fachzeitschriften
Allicin: A Medline Literature Survey
(Date: 26. April 2000)
Amantadin Stada 100mg (Cache date: June 30, 2005)
Manfred von Ardenne: Research on Hyperbaric
Oxygen Pressure Therapy and Cancer Therapy, A Medline-Literature
Survey (Date: 13. June 1999)
Asymptomatic Lyme, from: jwissmille@aol.com
(JWissmille), Newsgroups: sci.med.diseases.lyme, Subject: old post--asymptomatic
Lyme disease (28 Jan 1999)
Atovaquone (Meprone) - For educational
use only
Bakken LL, Callister SM, Wand PJ, Schell RF, Interlaboratory
comparison of test results for detection of Lyme disease by 516 participants
in the Wisconsin State Laboratory of Hygiene/College of American Pathologists
Proficiency Testing Program, J Clin Microbiol 1997 Mar;35(3):537-43
Barbour, AG, Advanced Query, Search
Field: Author, Suchbegriff: Barbour AG (31. July 1998)
Barkley MS, Transscript of a testimony,
New York State Assembly Standing Committee on Health, Public, Hearing "Chronic
Lyme Disease and Long-Term Antibiotic Treatment", Albany, NY, USA, (27.11.2001,
pp. 199 - 227).
Carol Ann Campbell, Hoffnung für
Lyme-Borreliose-Patienten, Star-Ledger, Medicine (4. Okt.2001)
Isolates of Borrelia spp.
Brand R and Kelman J, Physicians' Perspective
on Chronic Lyme, Rockland Journal-News (20. October, 2003)
Brorson O, Brorson SH, Henriksen TH, Skogen PR, Schoyen R., Association
between multiple sclerosis and cystic structures in cerebrospinal fluid,
Infection 2001 Dec;29(6):315-9
Burrascano JJ, 1994 California Lyme Disease
Symposium - Lyme Disease Resource Center of California
Clearance, Halbwertszeit
Lyme Disease: Studies on the Cystic Form of
Borrelia burgdorferi and Mechanisms of Persistence.
Original at Lymeinfo.net (September 2003)
-
Cystic Form of Bb: An Introduction (in cache, January 2011):
"These abstracts shed light on how Borrelia burgdorferi (Bb) is able to
survive antibiotic therapy, and on a primary mechanism underlying
post-treatment clinical relapses. They document the ability of Bb to
change from a spirochete-form to a "cystic" or coccoid form in response to
adverse environmental conditions. The cystic forms can later regenerate
spirochetes. 17 pages. Last modified: September 2003 "
- Cystic Form of Bb & Other
Spirochetes: Advanced:
"*Highly Recommended*. This file juxtaposes photographs and quotations
from
studies dating as far back as the early 1900's to show how spirochetes can
transform to and from cystic or coccoid forms. The ability of Bb and other
spirochetes to exist in coccoid forms provides a cogent explanation for
phenomenon such as latency, persistent infection, and seronegativity. A
picture is worth a thousand words!
30 pages. Last modified: September 2003"
-
Cystic Forms of Spirochetes: A
Complete
Bibliography, 1905-Present:
"Especially helpful for researchers. This file contains a complete bibliography of over 260 studies with information/observations on round forms of spirochetes (including 63 studies pertaining to Lyme disease), dating from the early 1900's to the present. Relevant quotations from the studies are included.
53 pages. Last modified: November 2010"
Cysts: Environmental Adaptation of Spirochetes
(09 Apr 2000)
Cysts: Historical Observations of Spirochetal
Cysts and L-Forms (09 Apr 2000)
Differentialblutbild,
H. Begemann: Praktische Hämatologie, 8. Aufl.; Stuttgart (1982)
Drulle J,
Uta Everth, U. Weller, A. Waldherr, VIIIth International Potsdam Symposium on Tick-borne Diseases, Jena, Germany, March 3 - 13, 2005 (im Cache)
Felice A, Brian A. Fallon, Psychiatric
and neuropsychological aspects of Lyme Disease, Meeting of the American
Psychiatric Association (2002)
Flagyl (Metronidazole) & CSF,
A Medline Literature Survey "metronidazole AND csf", Date: April 19, 2000
Gasser R, Orale Behandlung der späten
Lyme-Borreliose mit Roxithromycin und Co-trimoxazol, THE LANCET, VOL.
337, JAN 26, 1991, page 241
Generation Time, The generation
time of a single cell is the duration TG of a cell cycle, measured
as the time between two consecutive mitoses.
Golde WT et al., Immune Response and Western
Blotting, Literature selected by Kathleen M. Dickson and presented
Oct. 9, 1999 for comment at the Lyme-L Discussion List
Hanegraaf W, Simulating the Immune System
(August 10, 2001)
Lyme and Head, Neck and Hearing Disorders
Hydroxychloroquin - Chloroquin
(Engl. version):
-
Pharmacokinetische Daten,
-
Erklärung der Begriffe "Clearance", "Verteilungsvolumen" und Eliminationshalbwertszeit
-
Goodman & Gilman's "Pharmacological Basis of Therapeutics": Toxizität
und Nebenwirkungen
-
Hydroxychloroquin und Lyme
-
Weiterführende Literatur
The ILADS Working Group, Evidence-based guidelines for the management of Lyme disease, Expert Rev Antiinfect Ther 2004;2(1 Suppl):S1-13 (im Cache).
This report, completed in November 2003, is intended to serve as a resource for physicians, public health officials and organizations involved in the evaluation and treatment of Lyme disease. (Report Summary)
Highlights of Guidelines
- Since there is currently no definitive test for Lyme disease, laboratory results should not be used to exclude an individual from treatment.
- Lyme disease is a clinical diagnosis and tests should be used to support rather than supersede the physician's judgment.
- The early use of antibiotics can prevent persistent, recurrent, and refractory Lyme disease.
- The duration of therapy should be guided by clinical response, rather than by an arbitrary (i.e., 30 day) treatment course.
- The practice of stopping antibiotics to allow for delayed recovery is not recommended for persistent Lyme disease. In these cases, it is reasonable to continue treatment for several months after clinical and laboratory abnormalities have begun to resolve and symptoms have disappeared.
- in Cache: Diagnostic Concerns
- in Cache: Treatment Considerations, e.g. combination antibiotic treatment with
- oral amoxicillin, cefuroxime, or (more recently) cefdinir
combined with
- a macrolide (azithromycin or clarithromycin)
R B Stricker, A Lautin, J J Burrascano, Lyme disease: point/counterpoint, Expert Rev Anti Infect Ther. 2005 Apr;3(2):155-65. (in Cache)
Immune Electronmicroscopy:
Hazelton PR and Gelderblom HR, Electron Microscopy for Rapid Diagnosis
of Emerging Infectious Agents, Emerg Infect Dis [serial online] Volume
9, Number 3 (March 2003)
Models of Immune Systems: The Use
of Differential Equations, A Medline Literature Survey, (Date: 13. April
2000)
Lyme and Immune Complexes - A Medline
Literature Survey (Date: February 16, 2000)
Mathematical Immune Response Models
- A Medline Literature Survey (Date: March 29, 2000)
Stricker RB and Phillips SE, Endorsement
of Inadequate Treatment for Lyme Disease, Annals of Internal Medicine (submitted Marcj 2003)
Demonstrating the Intracellularity of Borrelia
burgdorferi, A compilation by Harold Smith (2000)
Klempner MS, Huber BT, Is it thee or me? - autoimmunity
in Lyme disease, Nature Medicine 5, 1346 - 1346-1347 (1999)
Kuby J, Immunology, 3.ed, W.H. Freeman and Co, New York (1997)
Leptospirose und Rattenurin
biologische Leukozytenkurve: Leukozytenverteilung
bei akutem bakteriellem Infekt [H. Begemann: Praktische Hämatologie,
8. Aufl.; Stuttgart 1982]
Luger SW, Lyme-Borreliose übertragen
von einer Stechfliege/Bremse, N. Engl.J.Med (NEJM). 1990 Jun 14;322(24):1752
Informationsveranstaltung des Borreliose Selbsthilfe
e.V. Berlin-Brandenburg (2001)
-
von Baehr R, Der Lymphozytentransformationstest für Borrelien:
Neue diagnostische Möglichkeiten für Problemfälle
-
Kursawe H, Klinik und Therapie der Neuroborreliose unter Einschluß
der Pulstherapie"
Luger SW, Lyme-Borreliose übertragen
von einer Stechfliege/Bremse, N. Engl.J.Med (NEJM). 1990 Jun 14;322(24):1752
Christen HJ, Hanefeld F, Eiffert H, Thomssen R, Epidemiology and clinical
manifestations of Lyme borreliosis in childhood.
A prospective multicentre study with special regard to neuroborreliosis,
Acta Paediatr Suppl 1993 Feb;386:1-75
Lyme Disease: Mechanisms, Resolution and
Therapeutic Vaccination - A Medline-Literature Survey (19. February,
1999)
Agarwal GS, (H.
Bungay, III, Professor Emeritus, ed.), Microbial
growth theory for biotreatment, Growth-limiting nutrient, TERM
PROJECT: MICROBIOLOGY OF TREATMENT PROCESSES, Howard P. Isermann Department
of Chemical & Biological Engineering, Department of Biomedical Engineering,
Rensselaer Polytechnic Institute, (Dec. 1994, Jan. 1995 and Feb.
1996)
Fallon BA, Neilds JA, Microbiology
of Borrelia burgdorferi, Special Article, The American Journal of Psychiatry
1994, 151:11, 1571-1583
Microbiology, Infections, and
Antibiotic Therapy, Grand Rounds Presentation, UTMB, Dept. of Otolaryngology
(22. March. 2000)
Gruber J, The Inadequacy of the Minimum
Inhibitory Concentration (MIC) concept - Illustrations.
When a bacteria population can be exposed to
an antibiotic in-vitro in the same way as it is in vivo, the in-vitro experiments quantify the efficacy of the antibiotic.
When the antibiotic has strong side effects, one has to
optimize between those effects and the risk of losing control over the
bacteria population. In such critical cases an in-vitro model with only
one parameter, the Minimum Inhibitory Concentration, may not be able to
describe the development of an in-vitro bacteria population accurately
enough.
Stein Goldings A, Controversies in neuroborreliosis,
Lyme Disease Conference (23 October, 1992)
Niches
Synonyms: immunologically priviledged or protected sites, protected states of existence (antigenic variation, cyst forms, slime layers)
There are at least 6 potential mechanisms (C. Pavia):
- antigenic variation (this is seen with the Borrelia species that cause tick-borne relapsing fever) or differential expression of antigens (especially the outer surface proteins; with B burgdorferi, only OspC is expressed during mammalian infection)
- production of an outer protective coat (eg, capsule, as seen with T pallidum)
- atypical forms (eg, cyst-like variants)
- incomplete immune response (eg, insufficient antibody , T-cell , or phagocytic response)
- deranged host immune response (eg, host-, tick-, or spirochete-derived immunosuppressive factors)
- other evasive factors (eg, motility)
Pavia C, Mechanisms of persistency of the Lyme disease spirochete. Program and abstracts of the 14th International Scientific Conference on Lyme Disease and Other Tick-Borne Disorders; April 21-23, 2001; Hartford, Connecticut.
An Appraisal of "Chronic Lyme Disease", Correspondence, N Engl J Med. 2008 Jan 24;358(4):428-431 (in Cache)
Original article: Feder HM Jr, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP; Ad Hoc International Lyme Disease Group, A critical appraisal of "chronic Lyme disease". N Engl J Med. 2007 Oct 4;357(14):1422-30
Relapse/Persistence of Lyme Disease Despite Antibiotic Therapy, LYME DISEASE MEDICAL LITERATURE SUMMARIES, Lyme Info, 16. September 2003
Analytic Perspective by Cameron DJ. Epidemiologic review of the generalizability of two clinical trials of Lyme disease conducted by Klempner et al., Epidemiologic Perspectives & Innovations, 2006
Pavlovic DM, Milovic AM, Dmitrovic R. Lyme Neuroborreliosis with Normal
Cerebrospinal Fluid Findings, VIIth International Congress Lyme
Borr, Abstract #D615 [Yugoslavian Study]
Neuroborreliose: Einige Hintergründe
für Krankheitsverlauf und lange Behandlungdauer, Literaturzusammenstellung, J. Gruber (2004)
Niches: Long-Term Inflammation in Lyme
Borreliosis, A Medline-Literature Survey (2001), augmented by J. Gruber
Garth L. Nicolson, PhD (Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, CA),
Reactivation of Illnesses, JWissmille@aol.com,
25 Aug 2002
Prostate Cancer Diagnosis
Fritz Schardt (Betriebsärztliche Untersuchungsstelle, Bayerische Julius-Maximilians-Universitat, Würzburg, Germany)
- A New Approach to Chronic Lyme Disease (im Cache)
... Diflucan behindert ein Enzym mit Namen Cytochrom P450. Dies ist ein Enzym, das z.B. unsere Leber benutzt, um Chemikalien und Medikamente in ungiftige Formen zu überführen. Borrelia hat eine sehr primitive P450-Abwehr, sodaß -wenn man es behindert-, es leicht geschwächt wird. Daher glaube ich, daß Diflucan das Wachstum und die Vermehrung von Borrelien behindert. Es bringt sie nicht notwendigerweise um. Zusätzlich dringt es gut in Zellen ein und ins Nervensystem und das Gehirn, wo die Borrelien sich verstecken könnten...
... Diflucan war damals [als ich es zuerst benutzte] ein neues Medikament, das hauptsächlich gegen opportunistische Pilzinfektionen bei AIDS-Patienten eingesetzt wurde...
- Clinical effects of fluconazole in patients with neuroborreliosis, Eur J Med Res. 2004 Jul 30;9(7):334-6.
Statine helfen gegen Multiple Sklerose - Deutschlandfunk, Forschung Aktuell, Newsletter, Kompaktinformationen aus Naturwissenschaft und Technik, 05.01.2005
Forscher fanden Substanz, die Entzündungen beim Nervensystem verlangsamen können.
Wirt-Pathogen-Wechselwirkung
Nature Insight: Host-microbe interactions, Nature Vol. 449, No. 7164:803-842. (Original)
Interactions between symbiotic or pathogenic microbes and the hosts they colonize are central to both health and disease. This rapidly advancing field is now bearing the fruits of interdisciplinary efforts by microbiologists, immunologists, cell biologists, geneticists and ecologists.
Artikel in Cache:
- Host-microbe interactions, Claudia Lupp, doi:10.1038/449803a (Original)
- The Human Microbiome Project, Peter J. Turnbaugh, Ruth E. Ley, Micah Hamady, Claire M. Fraser-Liggett, Rob Knight & Jeffrey I. Gordon, doi:10.1038/nature06244 (Original)
- An ecological and evolutionary perspective on human-microbe mutualism and disease, Les Dethlefsen, Margaret McFall-Ngai & David A. Relman, doi:10.1038/nature06245 (Original)
- Recognition of microorganisms and activation of the immune response, Ruslan Medzhitov, doi:10.1038/nature06246 (Original)
- Manipulation of host-cell pathways by bacterial pathogens, Amit P. Bhavsar, Julian A. Guttman & B. Brett Finlay, doi:10.1038/nature06247 (Original)
- Bacterial pathogenomics, Mark J. Pallen & Brendan W. Wren, doi:10.1038/nature06248 (Original)
|